Haytox: Botox for hay fever, explained honestly

What does "off-label prescribing" actually mean?

Off-label prescribing is the use of a licensed medicine outside the terms of its marketing authorisation. In the case of Haytox, botulinum toxin is a prescription-only medicine regulated by the MHRA, but it is not licensed specifically for allergic rhinitis or hay fever. That does not mean it is unlicensed or unsafe; it means the manufacturer has not applied for approval for this particular indication, often because the clinical trial work remains ongoing or the market is too small to justify a formal licence application.

Used appropriately, off-label medicines are a well-established and safe part of clinical practice, and they carry clear lines of responsibility. The prescriber takes responsibility for the decision and for overseeing the patient's care. At Visage Aesthetics, that means a face-to-face consultation, a detailed allergy history, an assessment of antihistamine efficacy, full informed consent about the off-label status, and use only of licensed botulinum toxin from a verified supplier. We document everything.

From 1 June 2025, all nursing and midwifery prescribers in the UK are required to consult face-to-face before prescribing aesthetic injectables, including botulinum toxin for any indication. This is a regulatory floor, not a ceiling; best practice exceeds it.

How does botulinum toxin reduce hay fever symptoms?

Botulinum toxin is an exotoxin produced by Clostridium botulinum. It works by blocking the release of acetylcholine at the neuromuscular and neuroglandular junction. In the context of allergic rhinitis, this has two relevant effects: it reduces mucus production from the nasal mucosa, and it modulates local inflammation.

Unlike systemic antihistamines or corticosteroids, which work throughout the body, Haytox delivers botulinum toxin directly to the nasal cavity via intranasal spray. The dose is small and localised, which is why systemic side effects are uncommon. The onset is not immediate, however; clinical effects typically emerge over days to weeks as the toxin diffuses into nerve terminals and blocks acetylcholine release.

What does the clinical evidence show?

The clinical evidence for botulinum toxin in refractory allergic rhinitis is emerging and promising, though the field is still young. A systematic review and meta-analysis published in 2026 found that botulinum toxin type A (BTX-A) significantly improved Total Nasal Symptom Score at both 4 weeks and 12 weeks post-treatment. Symptoms tracked included nasal congestion, rhinorrhoea (runny nose), and sneezing.

There is real clinical need behind this work. Many patients report limited satisfaction with traditional antihistamines, whether due to side effects, tolerance, or simply inadequate symptom control. Seasonal or perennial hay fever can be debilitating, affecting work, sleep, and quality of life. For those patients, Haytox may offer a bridge or alternative when first-line therapies have failed.

What we do not yet have is large, multi-centre randomised controlled trials comparing Haytox to other treatments, or long-term safety data spanning years. Early reports suggest relief lasting up to two months or longer, but that sits alongside claims of three-month effects. The truth is that individual variation is high, and more data is needed. Any practitioner offering Haytox should be clear about this uncertainty with their patients.

How is Haytox administered?

The treatment is administered via intranasal spray using a mucosal atomization device. The botulinum toxin is mixed with sterile saline and sprayed into each nostril in succession until the device is empty. Standard dosing in early trials has been 20 units of botulinum toxin type A per nostril, for a total of 40 units per treatment. The procedure takes only a few minutes and is painless.

There is no downtime. Patients can return to work or daily activities immediately. Transient nasal drip or mild congestion may occur in the hours after treatment, but this is not typical and resolves quickly.

Who should consider Haytox, and who should not

Haytox is not a first-line treatment. It is not a cosmetic procedure. It is a therapeutic option for patients with severe or refractory allergic rhinitis who have exhausted or failed to tolerate conventional management.

In my clinic, I consider Haytox for:

• · Patients with confirmed allergic rhinitis (ideally with allergy testing or specialist ENT assessment) whose symptoms are not adequately controlled by antihistamines or topical nasal corticosteroids.
• · Patients intolerant of antihistamines due to side effects such as drowsiness.
• · Those whose symptoms are seasonal but severe enough to justify a three-to-four week course of preparation before the pollen season begins.
• · Patients who have tried and failed other therapies, including intranasal corticosteroids, and are seeking an alternative.

Haytox is not appropriate for:

• · Patients with mild or moderate hay fever; standard antihistamines should be optimised first.
• · Those with active nasal infection or mucosal inflammation (treatment should be deferred).
• · Patients with neuromuscular disorders or those taking medications that interact with botulinum toxin.
• · People who are pregnant, breastfeeding, or planning pregnancy in the near term.
• · Any patient unwilling to commit to follow-up appointments and clear, documented informed consent about the off-label status and uncertainties.

Product safety and practitioner choice matter

In June and July 2025, the UK Health Security Agency confirmed 38 cases of iatrogenic botulism linked to unlicensed or counterfeit botulinum toxin injections administered in non-clinical settings. Industry bodies including the JCCP, BCAM, BAMAN, and Save Face jointly warned that only licensed products, qualified practitioners, and accredited clinics provide safety assurance.

This is not scaremongering. This is why Haytox must only ever be prescribed by a regulated healthcare professional (a doctor, nurse prescriber, or dentist with appropriate qualifications) using licensed botulinum toxin from a legitimate pharmaceutical supplier. At Visage, we use only licensed products, we maintain full traceability of every vial, and we work within established clinical governance. Your practitioner should be able to show you evidence of accreditation (Save Face, JCCP, or similar), current professional registration (NMC, GMC, or GDC), and clear product sourcing.

A short safety note

Botulinum toxin has a long-standing safety record in clinical use, with effects being fully reversible as the toxin is metabolised and acetylcholine function returns over weeks to months. That said, it is a potent drug, and systemic side effects are possible if doses are excessive or administration technique is poor. Bruising, mild headache, or transient nasal discomfort are the most common minor effects. Serious complications are rare but include botulism (excessive muscle weakness) if the practitioner is untrained or product is counterfeit.

This is why I do not recommend Haytox from unlicensed clinics, beauty therapists, or online telemedicine platforms offering it as a DIY or at-home treatment. Intranasal administration requires precision, sterile technique, and the ability to manage complications should they arise. If your hay fever is severe enough to justify an off-label injection, it deserves a qualified practitioner and a safe, verified setting.

Is Haytox right for you?

Haytox is not a miracle cure, and it is not for everyone. It is one option in a spectrum of management strategies for severe allergic rhinitis. If your hay fever is ruining your spring and summer, and you have already tried standard antihistamines and nasal corticosteroids, then a face-to-face consultation with a qualified practitioner to discuss Haytox might be worthwhile.

At Visage, I see patients for free consultation to assess whether Haytox is a sensible next step or whether there is scope to optimise existing treatments first. If you have questions about your eligibility, or simply want to understand the evidence and your options in detail, I encourage you to get in touch. We work to a high standard of informed consent and clinical governance, and I am happy to discuss the off-label status, the evidence, and the risks openly.

Common questions